Welcome to our dedicated page for Precision BioSciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision BioSciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (NASDAQ: DTIL) has reacquired global development and commercialization rights for its allogeneic CAR T programs from Servier, encompassing PBCAR0191, PBCAR19B, and four other targets. The transaction, valued at $1.25 million plus waived milestone payments of $18.75 million, enhances Precision's control over its clinical pipeline. CEO Matt Kane highlighted the promising nature of these CD19-targeting candidates, particularly PBCAR0191, which continues to yield favorable clinical results. The company expects sufficient cash reserves into 2023, facilitating ongoing operations.
Precision BioSciences, Inc. (Nasdaq: DTIL) announces the appointment of Dr. Stanley R. Frankel as a Director and member of the Science and Technology Committee. Dr. Frankel, a seasoned hematologist-oncologist, brings extensive experience in immuno-oncology and cellular therapies, having led programs for multiple FDA-approved drugs. His leadership is expected to aid Precision in advancing its CAR T and gene correction therapies. Dr. Tony Yao will continue his board term until May 10, 2021, after supporting the company through its transition to a public entity.
Precision BioSciences Inc. (Nasdaq: DTIL) announced that Dr. Derek Jantz, Chief Scientific Officer and Co-Founder, will participate in a fireside chat at the Truist Securities 2021 Life Sciences Virtual Series.
Event Details:Date: April 13, 2021Time: 11:00 AM ETA live webcast will be available on the company's website under the Investors & Media section, with a replay for approximately 30 days following the event.
Precision BioSciences focuses on developing innovative therapies using its proprietary ARCUS® genome editing platform.
Precision BioSciences (Nasdaq: DTIL) announced a transition plan to recruit a new Chief Executive Officer, with current CEO Matt Kane remaining in his role until a successor is found. The management team aims to advance CAR T programs, direct research against specific gene targets, and validate gene editing initiatives. While thanking Kane for his contributions, the board emphasizes the importance of identifying a leader to navigate the company's next growth phase and maximize opportunities within the ARCUS platform.
Precision BioSciences (Nasdaq: DTIL) announced its participation in the Guggenheim Healthcare Talks 2021 on April 1, 2021, focusing on genomic medicines and rare diseases. Dr. Derek Jantz, Chief Scientific Officer, will present on advancements in genomic medicine and cell therapy for dyslipidemia and Type 1 diabetes mellitus. The presentation will take place from 8:00-8:50 AM ET and will be accessible via a live webcast on the company's website, with an archived replay available for 30 days.
Precision BioSciences (NASDAQ: DTIL) reported a pivotal 2020, achieving significant advancements in its ARCUS genome editing and CAR T programs. The company announced a collaboration with Eli Lilly for developing gene therapies, receiving $100 million upfront. Financially, total revenues rose to $24.3 million, while R&D expenses increased to $98.1 million, reflecting growth in clinical programs. However, the net loss widened to $109 million, or $(2.09) per share. Key milestones for 2021 include initiating the PBCAR19B clinical trial and reporting interim data for multiple CAR T programs.
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its fourth quarter and fiscal year 2020 financial results and a business update on March 18, 2021. The company focuses on improving lives through its ARCUS® genome editing platform, which enables the development of CAR T immunotherapy clinical candidates and gene correction therapies. These advancements aim to address genetic and infectious diseases lacking adequate treatment options. For more information, visit www.precisionbiosciences.com.
Precision BioSciences (Nasdaq: DTIL) announced participation in two upcoming virtual investor conferences on March 9, 2021. The first is the H.C. Wainwright Global Life Sciences Conference, featuring an on-demand fireside chat starting at 7:00 AM ET. The second is the Barclays Global Healthcare Conference, with a presentation scheduled for 10:55 AM ET. Both events will be accessible via the company's website, ensuring investors can stay informed.
Precision BioSciences (Nasdaq: DTIL) announced a significant publication in Molecular Therapy detailing three-year follow-up results from a study on PCSK9 gene editing via its ARCUS® platform.
The study demonstrated a long-term reduction of LDL cholesterol levels by up to 56% in nonhuman primates after a single treatment, with stable reductions in PCSK9 protein levels by 85%. This data supports the potential for a one-time therapeutic approach to familial hypercholesteremia and highlights the efficacy and safety of ARCUS technology.
Precision BioSciences (Nasdaq: DTIL), a clinical stage biotechnology company, announced its participation in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 2:00 PM ET. A live webcast of the presentation will be available on the company’s website in the Investors & Media section. Precision BioSciences is focused on improving life through its proprietary ARCUS genome editing platform, which aims to develop CAR T immunotherapy and gene correction therapies for genetic and infectious diseases.